Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients
Author:
Publisher
Informa UK Limited
Subject
Pharmacology (medical),Oncology
Link
http://www.tandfonline.com/doi/pdf/10.1586/era.12.107
Reference97 articles.
1. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2. Molecular portraits of human breast tumours
3. Deconstructing the molecular portraits of breast cancer
4. Gene-Expression Signatures in Breast Cancer
5. Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
Cited by 20 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A Novel Signature Based on Angiogenesis-Related Genes Predicts the Prognosis and Immunotherapy Response in HER2-Positive Breast Cancer;Journal of Cancer;2024
2. Breast cancer liver metastasis: Pathogenesis and clinical implications;Frontiers in Oncology;2022-10-25
3. Long term continuous Trastuzumab use for HER2-positive advanced breast cancer;Journal of Contemporary Medical Sciences;2020-10-26
4. miR‐200c suppresses stemness and increases cellular sensitivity to trastuzumab in HER2+ breast cancer;Journal of Cellular and Molecular Medicine;2019-10-10
5. Assessment of the Molecular Mechanism of Action of SB3, a Trastuzumab Biosimilar;BioDrugs;2019-09-23
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3